AZN

Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep.

Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities.Dublin, Sept.

AstraZeneca received positive opinions from the EMA for Enhertu and Klygefa. Enhertu is seen as an adjuvant treatment for early‑stage HER2‑positive breast cancer, while Klygefa is an add‑on therapy for generalized myasthenia gravis.

Britain’s largest pharma firms warn that Europe’s drug industry is at risk. They cite a loss of ground to the U.S. and China in medical research.

Eli Lilly’s Inluriyo and Verzenio combination has received full FDA approval for advanced breast cancer. The approval is said to double progression‑free survival.

The article questions whether AstraZeneca’s current share price reflects its cash‑flow potential. It notes a 62.7% share price gain over five years and discusses valuation concerns.